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ABSTRACT
Purpose: Atrial fibrillation is the most common
arrhythmia. Its management aims to reduce symptoms
and to prevent complications through rate and rhythm
control, management of concomitant cardiac diseases
and prevention of related complications, mainly stroke.
The main objective of Effectiveness, Safety and Costs
in Atrial Fibrillation (ESC-FA) study is to analyse the
drugs used for the management of the disease in real-
use conditions, particularly the antithrombotic agents
for stroke prevention. The aim of this work is to
present the study protocol of phase I of the ESC-FA
study and the baseline characteristics of newly
diagnosed patients with atrial fibrillation in Catalonia,
Spain.
Participants: The data source is System for the
Improvement of Research in Primary Care (SIDIAP)
database. The population included are all patients with
non-valvular atrial fibrillation diagnosis registered in the
electronic health records during 2007–2012.
Findings to date: A total of 22 585 patients with
non-valvular atrial fibrillation were included in the
baseline description. Their mean age was 72.8 years
and 51.6% were men. The most commonly prescribed
antithrombotics were vitamin K antagonists (40.1% of
patients) and platelet aggregation inhibitors (32.9%);
25.3% had not been prescribed antithrombotic
treatment. Age, gender, comorbidities and co-
medication at baseline were similar to those reported
for previous studies.
Future plans: The next phase in the ESC-FA study
will involve assessing the effectiveness and safety of
antithrombotic treatments, analysing stroke events and
bleeding episodes’ rates in our patients (rest of phase
I), describing the current management of the disease
and its costs in our setting, and assessing how the
introduction of new oral anticoagulants changes the
stroke prevention in non-valvular atrial fibrillation.
INTRODUCTION
Atrial ﬁbrillation (AF) is the most common
form of chronic arrhythmia, with increasing
healthcare burden due to an ageing
Strengths and limitations of this study
▪ The limitations inherent in these studies are the
collection of non-randomised data or missing
information. Regarding the possible infraregister
of atrial fibrillation diagnosis, we have confirmed
that prevalence in our setting is comparable to
the prevalence reported in the available literature.
Given the inconsistencies found in the pharmacy
invoice registers, we had to exclude a high
number of patients. We were not sure about the
validity of these data and that is why they were
excluded. Therefore, we can confirm that the
information on drugs in this work is completely
reliable.
▪ Regarding the strengths of this study, it is neces-
sary to emphasise the large number of patients
included, and the coverage of our database and
the representativeness of the general population
(System for the Improvement of Research in
Primary Care (SIDIAP) information comes from
electronic health records of 5.8 million people—
more than 80% of the Catalan population), com-
plete socio-demographic data and real clinical
practice data. Moreover, this is the first population
study in our setting which assesses the number
of patients treated with the different pharmaco-
logical options traditionally used for stroke
prevention in atrial fibrillation in a real clinical
practice scenario; subsequently the study ana-
lyses the effectiveness and safety of these treat-
ments in terms of stroke and haemorrhage rates.
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population and improved survival rate from cardiovascu-
lar events.1 Its estimated prevalence is approximately 1–
2% of general population.1 2 AF increases with age,
from 0.5% in people under 502 to 10–15% in people
over 80 years of age.3
AF is associated with various cardiovascular conditions
such as hypertension, symptomatic heart failure or heart
valve disease. It increases the risk of stroke ﬁvefold, and
one in ﬁve strokes is attributed to this type of
arrhythmia.4
Management of patients with AF aims to reduce symp-
toms by means of rate and rhythm control, and the man-
agement of concomitant cardiac diseases to prevent AF
complications such as stroke and thromboembolism.4
Antithrombotic drugs used for stroke prevention in non-
valvular AF are oral anticoagulants (OAC), speciﬁcally
vitamin K antagonists (VKA), and antiplatelet agents.4
Recently, new OAC have received marketing authorisa-
tion in the European Union for stroke prevention: dabi-
gatran received authorisation in Spain in October 2011,
rivaroxaban in June 2012 and apixaban in August 2013.
The use of OAC and/or antiplatelet therapy depends
on the patient’s risk of developing thromboembolic and
bleeding events,5 6 taking into account that some risk
factors for bleeding are also risk factors for stroke.1 It is
generally recommended to assess stroke risk with
Congestive heart failure, Hypertension, Age, Diabetes
mellitus, Stroke (CHADS2)
7 8 and Congestive heart
failure, Hypertension, Age >75, Diabetes mellitus,
Stroke, Vascular disease, Age 65-74, female Sex
(CHA2DS2-VASc)
1 9 scores, and bleeding risk with the
Hypertension, Abnormal kidney and/or liver function,
Stroke, Bleeding, Labile INR, Elderly, Drugs and/or
alcohol (HAS-BLED) score.2 10 11
Net clinical beneﬁt of antithrombotic prophylaxis in
patients with AF has been demonstrated in some
studies.12 13 However, studies on OAC conducted in our
setting indicate underuse3 5 14–17 that is possibly due to
the VKA risk for bleeding; signiﬁcant interactions with
other drugs, food and alcohol; need for frequent INR
monitoring and the high interindividual and intraindivi-
dual variability in INR.1 4 In fact, the current number of
patients with AF under antithrombotic treatment in our
setting is unknown. Also, no data on the adequacy of
prescriptions based on stroke and bleeding risk exist.
Similarly, no studies on antithrombotic effectiveness in
stroke prevention in our setting have been published.
Therefore, the ageing population, which increases AF
and stroke incidences2 3; the recent approval of new
OAC for stroke prevention in non-valvular AF; and the
need to assess use of OAC and their clinical results
through population studies of the VKA most used in our
setting (acenocoumarol instead of warfarin, which has
been evaluated in most clinical trials) underscore the
need for the Effectiveness, Safety and Costs in Atrial
Fibrillation (ESC-FA) study.
The main objective of the ESC-FA study is to analyse
the drugs used for the management of non-valvular AF,
particularly the antithrombotic agents for stroke
prevention.
The study is divided into four different phases. The
speciﬁc objectives of phase I are: (1) to describe the
antithrombotic management of AF in our setting, (2) to
assess the effectiveness of antithrombotics in real-use
conditions according to stroke rates, and (3) to assess
the safety of antithrombotics use according to bleeding
events rates.
The speciﬁc objective of phase II is to describe the
management of rhythm and rate control. The speciﬁc
objective of phase III is to estimate the cost of managing
non-valvular AF in our setting. The speciﬁc objective of
phase IV is to assess changes in effectiveness, safety and
costs associated with the introduction of a new OAC.
In this paper, we present the protocol of phase I of
the ESC-FA study, with the description of baseline
characteristics of patients with non-valvular AF and the
drugs currently used for stroke and thromboembolism
prevention in our setting.
METHODS
Study design
The ESC-FA study is a retrospective observational
cohort study of ≥18-year-old individuals with a diagnosis
of non-valvular AF and registered in the electronic
health records throughout 2007 and 2012 in all
primary care centres of the Catalan Health Institute
(ICS). The ICS is the main provider of health services
in Catalonia and it manages 274 primary care practices
with a catchment population of 5 835 000 patients
(80% of the Catalan population, or more than 10% of
the Spanish population).
Data source
The data source is System for the Improvement of
Research in Primary Care (SIDIAP) database. SIDIAP
contains anonymised clinical information that originates
from different data sources:18–22 (1) eCAP (electronic
health records in primary care of the ICS) which
includes information since 2006 on sociodemographic
characteristics, health conditions registered as
International Classiﬁcation of Diseases (ICD)10 codes,
general practitioners’ prescriptions, clinical parameters
and toxic habits; (2) laboratory data; (3) prescriptions
and their corresponding pharmacy invoice data that are
available since 2005, with information on all pharma-
ceutical products dispensed by community pharmacies
for Catalan Health System prescriptions, by Anatomic
Therapeutic Chemical Classiﬁcation System (ATC)
codes; (4) the CMBD-AH database that includes diagno-
ses at hospital discharge registered as ICD9 codes.
Study population
Inclusion criteria: all patients older than 18 years with a
new diagnosis of non-valvular AF registered in SIDIAP
from 2007 to 2012.
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Exclusion criteria: valvular AF and antithrombotic treat-
ment registered more than 6 months before the AF
diagnosis.
The cohorts were deﬁned according to the antithrom-
botic treatment registered in the pharmacy invoice data-
base at the time of diagnosis by considering an overall
6-month period for the deﬁnition of baseline date
(±3 months between diagnosis date and antithrombotic
treatment date). All patients with more than one dis-
pensed package of an antithrombotic registered in this
period of time were included in the study.
To deﬁne dual therapy at baseline (VKA + antiplatelet,
or aspirin + another antiplatelet), we considered at least
two consecutive entries in the pharmacy invoice data-
base for both drugs during the baseline period.
Two consecutive entries are all those separated by a
period of time equal to the period of supply of a drug
package. For instance, for 1-month treatment packages,
consecutive entries are those separated by a 1-month
interval in the pharmacy invoice register.
Study variables
At baseline, the following variables were collected: gender;
age at diagnosis; Mortalidad en áreas pequeñas
Españolas y Desigualdades socioEconómicas y
Ambientales (MEDEA) Index (deprivation index which
shows the social or material disadvantage accruing to a
person or group in accordance to their city/region/
country, as given in the census data in Catalonia. The
higher this is, the worse the deprivation23; smoking
status (last register before diagnosis); alcohol intake (last
register before diagnosis); body mass index (nearest
value to diagnosis date, within an interval of ±2 years of
diagnosis date); stroke and bleeding risk (CHADS2 and
HAS-BLED were calculated at baseline with the informa-
tion registered in SIDIAP; for bleeding risk, HAS-BLED
was calculated without ‘L: labile INR’ item, since INR
values were missing in most patients); comorbidities of
interest and cardiovascular risk factors registered before
AF diagnosis (cardiovascular comorbidities, previous
bleedings, and kidney and liver function given as ICD10
codes speciﬁed in the ICD10 codes list; see online sup-
plementary ﬁle); laboratory data (the nearest value to
diagnosis date, within an interval of ±1 year of diagnostic
date); blood pressure (BP, the nearest values of systolic
and diastolic BP to diagnosis date, within an interval of
±1 year of diagnosis date); antithrombotic drugs regis-
tered in the pharmacy invoicing database within
±3 months from diagnosis date (registered as ATC codes
speciﬁed in the ATC codes list; see online supplementary
ﬁle); concomitant drug therapy of interest registered in
the pharmacy invoice database within ±3 months from
diagnosis date (rate and rhythm control drugs, other car-
diovascular medication, diabetes treatments, proton
pump inhibitors, and non-steroidal anti-inﬂammatory
drugs listed as ATC codes speciﬁed in the ATC codes
list; see online supplementary ﬁle); stroke and other
thromboembolic events rates and bleeding episodes
(cerebral, gastrointestinal, eye and other haemorrhages)
rates registered at CMBD-AH before AF diagnosis in
order to conﬁrm the stroke and bleeding rates registered
at SIDIAP (as ICD9 codes speciﬁed in the ICD9 codes
list; see online supplementary ﬁle).
During follow-up the following variables will be assessed
for objectives 2 and 3: stroke and bleeding risk calcu-
lated during follow-up; stroke and other thrombo-
embolic events and haemorrhages rates; antithrombotic
drugs taken during follow-up to assess treatment
changes, new treatments or end of treatment, and
analysis of effectiveness and safety of the main treat-
ment options—VKA, antiplatelet drugs and no antith-
rombotic treatment—through the variable ‘net clinical
beneﬁt’.
‘Net clinical beneﬁt’ has been deﬁned in a previous
publication24 as the annualised rate of thromboembolic
events prevented minus the annualised rate of intracra-
nial haemorrhages (ICHs) induced multiplied by a
weighting factor of 1.5; this reﬂects the relative impact,
in terms of disability, of an ICH while receiving VKA
(studied with warfarin) versus experiencing an ischae-
mic stroke while not receiving VKA:
Net clinical benefit = ðstroke rate off  VKA
 stroke rate on VKAÞ  1:5 ðICH rate on VKA
 ICH rate off  VKAÞ
Statistical analysis
Descriptive statistics were used to summarise the data.
Categorical variables were expressed as frequencies
(percentage) and quantitative variables as mean (SD)
or median (IQR) for non-normally distributed vari-
ables. The differences between cohorts were tested
using analysis of variance or Kruskal-Wallis test, χ2 or
Fisher exact test for unadjusted comparison, as
appropriate.
Incidence rates and incidence rate ratios of stroke and
bleeding events during the follow-up will be estimated
using Poisson regression. The resulting person-time value
will be used as an offset variable. Time-to-event analysis
will be performed using non-parametric methods like
Kaplan-Meier and log-rank test. Multivariate Cox propor-
tional hazards regression models will be ﬁtted, adjusting
for baseline sociodemographic characteristics, and con-
founding and predictive factors of each event. Extended
Cox models will be used when the model’s proportional
hazards assumption does not hold.
Sensitivity analysis will be carried out excluding
patients who change from one cohort to another during
the follow-up and censoring according to the patient’s
change of cohort.
All statistical tests were two-tailed using a signiﬁcance
level of 5%. The analyses were performed using Stata
V.11 (Stata Corp, Collage Station, Texas, USA) and R
V.3.0.2 (R Foundation for Statistical Computing, Vienna,
Austria).
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Ethical and legal issues
The present study follows national and international reg-
ulations: Declaration of Helsinki Ethical Principles for
Medical Research Involving Human Subjects, and Good
Research Practice principles and guidelines.
Regarding the data contained in the databases and as
per Spanish legislation about conﬁdentiality and data
protection (Ley Orgánica 15/1999 de 13 de diciembre
de Protección de Datos de Carácter Personal), data
included in SIDIAP are always anonymised and identi-
ﬁed by an internal code, which makes it impossible to
identify the individuals included. Thus, it is not neces-
sary to ask for informed consent from the participants.
Each individual is identiﬁed through an encrypted,
anonymised code.
For the linkage with CMBD database (or other data-
bases), SIDIAP uses a ‘trusted third party’ in order to
ensure conﬁdentiality when linking both data sources.
This third party has no access to clinical information,
only to codes and IDs.
Cohort description and findings to date
There were 41 468 patients with a new AF diagnosis
registered in SIDIAP between 2007 and 2012. Of the
newly diagnosed patients, 25 601 (61.7%) fulﬁlled the
inclusion criteria and none of the exclusion criteria
(ﬁgure 1). Study cohorts were based on antithrombotic
treatment registered at the time of AF diagnosis
(±3 months interval). Two treatment groups were
excluded from the baseline description of the cohorts
(11.8% of patients included): patients with only 1 dis-
pensed package of antithrombotic registered during
study period (n=1755) and patients with ≥3 different
antithrombotic drugs registered (n=1261), as this is a
group that is excessively heterogeneous.
We present the baseline characteristics of 22 585 indi-
viduals with non-valvular AF, diagnosed from 2007 to
2012. Their mean age was 72.8 (SD 13.1) years and
51.6% were men. The number of patients diagnosed per
year with AF in each cohort is shown in ﬁgure 2.
There were 5724 (25.3%) of patients with no antith-
rombotic treatment registered at baseline. The most pre-
scribed treatment were VKA (9057 patients, 40.1%),
followed by platelet aggregation inhibitors (7424,
32.9%). The remaining patients were initiated on VKA +
antiplatelet (1.0%) or on dabigatran (0.7%).
During the study period, the proportion of patients
with no antithrombotic treatment decreased from 28.2%
in 2007 to 26.1% in 2012, while the proportion of
VKA-treated patients increased from 37.5% in 2007 to
41.8% in 2012. A decrease in the prescription of antipla-
telet agents, from 33.4% in 2007 to 27.9% in 2012, was
observed.
The baseline characteristics of our patients, including
percentages of patients with missing data, are described
in tables 1–4.
Table 1 shows higher proportions of men in all cohorts
except in the antiplatelet group. Patients treated with any
antithrombotic drug were older than non-treated
patients. There were more patients over 75 years in the
group of antiplatelets. There were more current smokers
in the group of patients with no antithrombotic treat-
ment; however, this group had a higher percentage of
missing values than the rest of the groups. There was also
a high percentage of missing values in alcohol intake.
Considering only the three main cohorts (no treat-
ment, VKA, antiplatelets) and according to a CHADS2
score ≥2, 52.8% of the patients from the VKA cohort
would be considered as ‘adequately anticoagulated’.
According to a CHA2DS2VASc score ≥2, 62.6% of VKA
patients would be ‘adequately anticoagulated’ and at
least 6.1% of patients in the same group
(CHA2DS2VASc=0) would be ‘inadequately anticoagu-
lated’ as their stroke risk is low (ﬁgure 3).
On the other hand, there are 38.8% patients in the
no-treatment group with a CHADS2 score ≥2; so they
should be receiving VKA. This percentage is 65.5% if we
take into account the CHA2DS2VASc score (≥2); thus,
only 34.5% patients with a low-moderate stroke risk are
not treated with antithrombotics.
Patients treated with antiplatelets and VKA + antiplate-
lets have higher scores in the HAS-BLED bleeding
classiﬁcation.
Table 2 shows that patients with antithrombotic treat-
ment had more cardiovascular comorbidities when com-
pared with non-treated patients, and patients in the dual
therapy VKA + antiplatelet cohort had more comorbidity.
Hypertension was the most frequent comorbidity,
followed by dyslipidaemia. Coronary artery disease was
found in 34.8% of the patients in the VKA + antiplatelet
cohort, with a high frequency of previous myocardial
infarction. Non-treated individuals had better estimated
glomerular ﬁltration rate (eGFR) than patients initiated
on antithrombotic therapy, except for dabigatran (84.4%
of dabigatran patients had eGFR >60 mL/min/1.73 m2).
However, there were more missing values in that group.
Disease control parameters and laboratory data of
interest are described in table 3. Around two-thirds of
patients had good control of BP, glycated haemoglobin
and low-density lipoprotein cholesterol levels without dif-
ferences between cohorts.
We describe medications of interest in use at baseline
in table 4. Patients with antithrombotic prescribed at
baseline received more co-medication than non-treated
patients, since they had more comorbidity.
Antihypertensive drugs, statins and proton pump inhibi-
tors were the most frequent co-medications.
All baseline sociodemographic characteristics and
comorbidities were signiﬁcantly different among the ﬁve
groups.
DISCUSSION
The ESC-FA study was designed as a retrospective obser-
vational cohort study on the effectiveness and safety of
antithrombotic therapy in patients with non-valvular AF
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that was in use under clinical conditions in Catalonia. In
this article, we report the baseline sociodemographic
and clinical characteristics of 22 585 patients with non-
valvular AF recently diagnosed, and discuss the main dif-
ferences between non-treatment and usual treatments
for prevention of stroke and thromboembolic events.
The patients included in the study have been divided
into ﬁve cohorts according to the antithrombotic treat-
ment prescribed at the time of diagnosis.
This is an observational study performed with data
obtained from an electronic database. Therefore, it is
subject to certain limitations inherent in all such studies,
such as the collection of non-randomised data, missing
or incomplete information, and possible confounders.
The strengths of our study are the large number of
patients included, representativeness of the general
population (SIDIAP information comes from ICS, which
manages more than 80% of the Catalan population),
Figure 1 Study flow chart. Patients included and excluded from the study. AF, atrial fibrillation; SIDIAP, System for the
Improvement of Research in Primary Care; VKA, vitamin K antagonist.
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complete sociodemographic and health records, and
real clinical practice data.
With regard to AF diagnosis, our data are supported
by previous studies18–21 which validate our ﬁndings
and indicate that the study population is representative
of the population in Catalonia and thus can be used
in epidemiological studies in our setting. More specif-
ically, the diagnosis of AF has been validated in our
population in the study published by García-Gil
Mdel et al.22
The diagnosis is sometimes registered in the patients’
electronic health records after the real diagnosis has
been made, and the start of antithrombotic treatment is
registered before or after the diagnosis register. To over-
come this inconsistency, the cohorts have been con-
structed taking into account antithrombotic treatments
registered during the interval of ±3 months from the
diagnostic date.
Regarding the pharmacy invoicing register, we have
excluded 11.8% of the 25 601 patients with non-valvular
AF due to inconsistencies in the register of treatments.
We decided to exclude 1261 patients as they had regis-
ters of three or more different antithrombotic drugs sim-
ultaneously at baseline and we assumed there might be
errors in the pharmacy invoice database. We decided to
exclude another 1755 patients from the baseline descrip-
tion of the cohort because they only had one package of
antithrombotic medication dispensed and there were
dispensing errors.
Although most patients are treated with VKA, INR
data are not described at baseline because two different
methods of INR determination are used in Catalonia: by
laboratory standard determination, which is performed
in a low proportion of patients; or through a
point-of-care rapid INR determination carried out
during primary care visits or in hospitals in most cases.
Since we do not have access to hospital records, a high
number of INR had missing values. Therefore, INR has
not been included in the HAS-BLED calculation.
However, at this stage it should not make a signiﬁcant
Figure 2 Distribution of new
diagnoses of atrial fibrillation (AF)
per year and cohort. Percentage
of patients newly diagnosed with
AF per year in each cohort in the
figure, number of patients in the
table below. Vitamin K
antagonists (VKA; n=9057);
antiplatelets (n=7424); VKA +
antiplatelet (n=227); dabigatran
(n=153); no antithrombotic
treatment (n=5724).
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difference, since INR is only determined in VKA-treated
patients during follow-up and we present the data at
baseline, when the INR has not yet been determined
and the ‘L’ for HAS-BLED is 0, the same as in patients
not treated with VKA. Nonetheless, we will conduct a val-
idation for the INR during the follow-up period as it is
an essential parameter in the clinical management of
VKA-treated patients.
Regarding sociodemographic characteristics, the pro-
portion of men and women in our study is quite
balanced (51.6% of men) and this is similar to that in
prior registries.15 27 28
We found that patients treated with any antithrombo-
tic drug are older, have more comorbidity at baseline
and receive more co-medication than non-treated
individuals. In agreement with similar studies, we
found high prevalence of hypertension, dyslipidaemia,
diabetes mellitus and heart failure in all patients with
AF.27 29–31
The number of patients included in the VKA + antipla-
telet cohort is low, possibly due to the short interval of
time used to consider a situation of dual therapy (two
consecutive registers of both drugs at baseline). The
number of patients included in the dabigatran cohort is
also low, since this drug was authorised for non-valvular
AF in Spain at the end of 2011 and we only include data
up to 2012. Moreover, dabigatran is subject to restricted
conditions for its prescription in our setting. Data for riv-
aroxaban are not shown, since there were only a few reg-
isters during 2012. Data for apixaban are not shown
either, as it was authorised in Spain for non-valvular AF
in 2013. VKA prescription rate in patients with non-
valvular AF at baseline is similar to those in other studies.
Kirchhof et al29 conducted an observational study
(PREvention oF thromboemolic events—European
Registry in Atrial Fibrillation, PREFER-AF) including
7243 patients in seven European countries between
January 2012 and January 2013. In the cross-sectional
Table 1 Sociodemographic characteristics and cardiovascular, stroke and bleeding risk factors
No antithrombotic
treatment VKA
Antiplatelet
agents VKA + antiplatelet Dabigatran
n=22 585 5724 9057 7424 227 153
Gender
Female (%) 46.9 48.3 50.3 36.6 38.6
Male (%) 53.1 51.7 49.7 63.4 61.4
Age (years; mean, SD) 69.6 (16.4) 73.4 (10.3) 74.6 (12.9) 72.4 (9.9) 71.4 (11.0)
>75 years (%) 45.5 51.1 53.6 43.6 39.2
MEDEA23 (mean, SD) 0.44 (0.92) 0.52 (0.90) 0.50 (0.91) 0.51 (0.82) 0.29 (0.97)
≥4th quintile (%) 36.6 39.4 39.1 41.0 29.9
BMI (kg/m2; mean, SD) 28.6 (5.1) 30.2 (5.3) 29.2 (5.2) 30.1 (5.5) 29.5 (4.4)
BMI ≥30: obesity (%) 34.7 46.8 38.8 44.4 40.2
Missing values (%) 46.4 25.3 33.9 25.6 39.9
Smoking status (%)
Non-smoker 65.7 70.0 70.3 62.8 66.2
Current smoker 16.9 10.3 11.8 12.2 9.6
Ex-smoker 17.4 19.7 17.9 25.0 24.2
Missing values 30.9 19.5 18.4 17.2 11.1
Alcohol intake (%)
Non-consumer 71.8 70.3 70.4 67.5 63.3
Mild-moderate 25.7 27.3 27.2 31.3 32.7
Alcohol abuse 2.5 2.4 2.4 1.2 4.1
Missing values 49.0 29.0 35.2 26.9 35.9
CHADS2 score
7 (%)
0 31.7 15.3 19.9 11.9 18.3
1 29.6 31.9 32.6 31.3 38.6
2 24.8 34.8 30.6 27.8 26.1
≥3 14.0 18.0 16.9 29.1 17.0
CHA2DS2VASc score
25 (%)
0–1 34.5 17.8 22.3 13.6 24.2
2 16.5 19.5 19.2 18.5 24.8
3 21.4 26.6 23.8 26.4 20.3
≥4 27.6 36.0 34.7 41.3 36.8
HAS-BLED score10 11 (%)
0 16.3 6.6 0.0 0.0 4.1
1–2 63.6 68.9 42.5 34.3 81.6
≥3 20.2 24.4 57.4 65.7 14.3
BMI, body mass index; VKA, vitamin K antagonists.
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Table 2 Baseline comorbidities
No antithrombotic
treatment VKA
Antiplatelet
agents VKA + antiplatelet Dabigatran
n=22 585 5724 9057 7424 227 153
Cardiovascular comorbidity (%)
Hypertension 48.1 65.1 59.5 67.8 64.1
Years of evolution (mean, SD) 7.4 6.8 6.8 7.1 5.9
Type 2 diabetes mellitus 14.4 18.5 16.7 26.4 16.3
Years of evolution (mean, SD) 6.9 6.9 6.4 6.5 9.4
Dyslipidaemia 24.8 33.2 31.7 38.3 31.4
Peripheral arterial disease 0.9 1.1 1.5 4.0 2.6
Coronary artery disease 4.3 2.8 5.7 34.8 3.9
MI 1.4 0.7 2.1 17.2 0.7
Angina 1.1 1.0 1.6 7.5 2.0
Heart failure 7.7 10.0 8.1 13.2 5.2
Previous stroke 4.8 7.2 5.3 14.1 8.5
TIA 1.0 1.6 1.8 5.3 4.6
Bleeding (%)
Previous bleeding 6.0 4.5 5.1 4.0 7.8
Cerebral haemorrhage 1.0 0.4 0.8 0.4 2.0
Gastrointestinal 3.6 2.5 2.9 1.3 3.9
Eye 0.4 0.7 0.6 0.4 0.0
Other 1.3 0.9 1.0 1.8 2.6
Peptic ulcer 3.6 3.7 3.8 2.2 2.6
Renal impairment (%)
eGFR (MDRD)
<30 mL/min/1.73 m2 2.4 1.9 2.4 1.6 0.0
30–60 25.4 27.7 28.7 36.0 15.6
>60 72.2 70.4 68.9 62.4 84.4
Missing values 35.0 18.1 19.1 16.7 28.8
Hepatic impairment (%) 3.2 1.7 1.6 2.2 0.7
Charlson comorbidity index26 (%)
0–2 88.6 90.6 89.1 88.5 92.2
>2 11.4 9.4 10.9 11.5 7.8
eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; MI, myocardial infarction; TIA, transitory ischaemic
attack; VKA, vitamin K antagonists.
Table 3 Disease control parameters and laboratory data
No antithrombotic
treatment VKA
Antiplatelet
agents
VKA +
antiplatelet Dabigatran
n=22 585 5724 9057 7424 227 153
BP
Systolic BP (mean, SD) 132.5 (19.3) 133.3 (18.5) 133.5 (18.4) 132.3 (18.3) 131.6 (17.7)
Diastolic BP (mean, SD) 76.6 (11.7) 78.0 (11.8) 77.2 (11.4) 77.0 (11.9) 77.5 (11.8)
Good BP control (<140/90 mm Hg; %) 64.6 61.5 61.3 63.7 65.9
Missing values 22.5 6.8 10.0 5.3 11.8
HbA1c (mean, SD) 1.4 1.3 1.3 1.3 1.1
HbA1c <7% (%) 70.5 65.5 69.7 55.7 74.0
Missing values 77.8 66.5 69.2 57.3 67.3
Total cholesterol (mg/dL) (mean, SD) 195.7 (40.8) 198.3 (39.5) 195.1 (39.5) 183.3 (42.5) 199.0 (36.6)
HDL 53.0 (15.1) 53.1 (14.3) 53.9 (15.1) 51.1 (14.0) 54.3 (14.6)
LDL 120.9 (34.3) 121.6 (33.8) 119.3 (33.5) 109.1 (36.1) 125.1 (28.2)
n, per cent of c-LDL <130 mg/dL 61.0 61.0 63.5 72.4 59.6
Missing values of total cholesterol (%) 35.4 18.7 19.7 15.9 29.4
BP, blood pressure; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; c-LDL, low-density lipoprotein-cholesterol; VKA, vitamin K
antagonists.
8 Giner-Soriano M, et al. BMJ Open 2016;6:e010144. doi:10.1136/bmjopen-2015-010144
Open Access
description, their results suggest much better adherence
to evidence and recommendations than previous reports
of similar registries: VKA were prescribed in 66.3% of
the patients included, antiplatelets in 11.2%, VKA + anti-
platelet dual therapy in 10.9%, and dabigatran in 6.1%.
They reported 17.7% of non-treated individuals. Results
from a prospective follow-up study have not been pub-
lished as yet.
Kakkar et al30 conducted the GARFIELD study in dif-
ferent primary care settings, which described VKA
prescription in 45.2% of patients with AF, antiplatelet
agents in 25.3%, dual therapy VKA + antiplatelet in
10.6% and dabigatran in 4.5%. They included 10 614
patients enrolled throughout 2009 and 2011. This study
reported similar VKA and antiplatelet prescription rates
to those found in our setting.
Scowcroft et al31 conducted a cohort study of 81 381
patients with AF from the General Practice Research
Database, diagnosed with AF between 2000 and
2009. They found differences in VKA prescription
Table 4 Medications in use at baseline (% of patients)
No antithrombotic
treatment VKA
Antiplatelet
agents VKA + antiplatelet Dabigatran
n=22 585 5724 9057 7424 227 153
Digoxin 4.4 20.3 13.5 11.9 10.5
Amiodarone 7.9 18.3 14.6 23.3 9.2
Flecainide 4.3 4.4 6.1 3.1 9.2
Dronedarone 0.3 0.7 0.6 0.0 0.7
Other antiarrhythmic agents 1.9 1.9 2.2 0.9 2.0
Diuretics
Low-ceiling diuretics 10.3 25.6 20.4 29.1 11.8
Thiazides 4.8 9.3 8.4 4.8 7.2
Aldosterone antagonists 1.8 3.4 2.2 5.3 0.7
β-blockers 11.3 30.4 23.0 48.5 38.6
Calcium channel blockers
Dihydropiridines 6.1 11.9 9.9 15.0 7.2
Verapamil 1.0 1.6 1.1 0.4 0.7
Diltiazem 1.8 9.3 5.0 5.7 6.5
ACEI 13.9 30.1 26.2 40.1 24.2
ARB 10.6 22.3 17.2 19.4 27.5
Other antihypertensive drugs 1.8 4.3 3.1 5.7 4.6
Nitrates 1.4 2.4 4.4 19.4 0.0
Trimetazidine 1.5 1.8 2.6 2.2 2.0
Ivabradine 0.1 0.1 0.3 0.9 0.0
Other vasodilator agents 0.2 0.4 0.3 0.4 0.0
Statins 11.3 24.3 22.7 52.4 22.2
Other lipid-modifying agents 1.4 2.0 1.8 4.0 2.0
Oral antidiabetic agents 5.8 12.8 10.3 21.1 12.4
Insulins 1.4 2.4 2.2 4.0 1.3
Proton pump inhibitors 25.5 42.9 53.7 69.2 32.7
NSAIDs 15.5 19.0 20.6 18.5 8.5
ARB, angiotensin receptor blockers; NSAID, non-steroidal anti-inflammatory drugs.
Figure 3 CHA2DS2VASc scores
in the treatment cohorts.
Percentage of patients from each
cohort by stroke risk according to
CHA2DS2VASc score. VKA,
vitamin K antagonist.
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according to the age group: in the 60–69 years age
group, VKA was prescribed to 57% of the patients;
in the 70–79 years age group, 55% of patients were
receiving VKA; and only 32% of patients older than
80 years were treated with VKA. Although this study
was carried out with data from an electronic database,
which makes possible the analysis of a large set of
patients, the results are not easily comparable to ours
since we have not stratiﬁed patients by age group. In
our study, 51.1% of the VKA group are over 75 years
of age.
Observational studies conducted in our setting
described different proportions of patients treated with
VKA14 15 28 than those found in our study (table 1 and
ﬁgure 3). Nevertheless, we described the situation only
at baseline date and our patients could start antithrom-
botic treatment during follow-up. Moreover, these studies
included small numbers of patients. The adequacy of
anticoagulation is described in some of these studies;
Kirchhof et al29 describe 85.6% of patients adequately
anticoagulated (CHA2DS2-VASc ≥2). In our study, there
are less patients adequately anticoagulated (62.6% of
VKA patients had CHA2DS2-VASc ≥2), but only 6.1% of
patients with truly low risk (CHA2DS2-VASc=0) received
VKA at baseline; this proportion of inadequate anticoa-
gulation is higher in other studies.28 30
Kakkar et al30 and Barrios et al28 describe 61.9% and
57% of patients adequately anticoagulated, respectively,
by considering CHADS2 score. On the other hand,
Scowcroft et al31 included 90% of patients with a
CHA2DS2-VASc score ≥2, but only 45.6% of the patients
included received warfarin. Although it is difﬁcult to
compare our study with prior reports, even if the pre-
scription of OAC in our setting appears to be low, it is
nonetheless similar to other studies.
CONCLUSIONS
We describe the actual use of antithrombotic agents for
stroke and thromboembolism prevention in a large
number of patients with non-valvular AF in Catalonia.
Age, gender and comorbidity in patients with non-
valvular AF were similar to those reported in previous
studies. The prescription rates of patients initiated on
VKA and on platelet aggregation inhibitors were similar
to those reported in other studies.
We cannot establish any conclusion about dabigatran
use, since only 153 patients had been initiated on this
new OAC as its approval for use in patients with AF took
place in latter 2011. This is expected to change during
follow-up, when more patients will have been included
in the dabigatran cohort and will have started treatment
with rivaroxaban and apixaban as well.
The next step in ESC-FA study is to assess effectiveness
and safety of antithrombotic treatments by analysing
stroke and other thromboembolic events, and haemor-
rhage rates in our patients. These data would show
changes in the management of patients with non-
valvular AF in Catalonia due to modiﬁcations in antith-
rombotic treatment during follow-up and the introduc-
tion of the new OAC.
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